11 research outputs found
Hazai tapasztalatok metasztatikus kolorektális karcinóma bevacizumabbal kiegészített indukciós kemoterápiás kezelésével (AVACONT vizsgálat)
The primary aim of AVACONT was to collect data in the course of routine oncological care from patients with metastatic colorectal cancer (mCRC) treated with bevacizumab supplemented fluoropyrimidine-based chemotherapy doublet in an open, multicentre, observational study in Hungary. Primary endpoint of the study was to determine progression-free survival (PFS). The Full Analysis Set (FAS) comprised 280 patients. Median PFS calculated from enrolment was 270 days in the FAS population. The metastatic involvement of the liver or more than one organ significantly decreased (250 and 245 days), while a clinical response achieved significantly increased (partial response: 404, complete response: 623 days) the mPFS calculated from enrolment. PFS calculated from the start of the first-line treatment was significantly decreased by the presence of mutant RAS gene (481 vs. 395 days). The results confirm the efficacy, known prognostic factors and safety profile of bevacizumab in combination with chemotherapy dosed during standard oncology care in Hungarian centres
Kynurenic acid inhibits intestinal hypermotility and xanthine oxidase activity during experimental colon obstruction in dogs
Kynurenic acid (KynA), an endogenous antagonist of N-methyl-D-aspartate
(NMDA) glutamate receptors, protects the central nervous system in
excitotoxic neurological diseases. We hypothesized that the inhibition
of enteric glutamate receptors by KynA may influence dysmotility in the
gastrointestinal tract. Group 1 of healthy dogs served as the
sham-operated control, in group 2, the animals were treated with KynA,
while in groups 3 and 4 mechanical colon obstruction was maintained for
7 h. Group 4 was treated with KynA at the onset of ileus. Hemodynamics
and motility changes were monitored, and the activities of xanthine
oxidoreductase (XOR) and myeloperoxidase (MPO) were determined from
tissue samples. Colon obstruction induced a hyperdynamic circulatory
reaction, significantly elevated the motility index and increased the
mucosal leucocyte accumulation and the XOR activity. The KynA treatment
augmented the tone of the colon, permanently decreased the motility
index of the giant colonic contractions and reduced the increases in
XOR and MPO activities. These effects were concomitant with the in
vitroinhibition of XOR activity. In conclusion, KynA antagonizes the
obstruction-induced motility responses and XOR activation in the colon.
Inhibition of enteric NMDA receptors may provide an option to influence
intestinal hypermotility and inflammatory changes